ERBB2 and breast cancer: There were five breast cancer outcomes (luminal A-like, luminal B-like, luminal B human epidermal growth factor receptor 2 [HER2] negative-like, HER2 enriched-like, and triple-negative), five lung cancer outcomes (ever-smokers only, never-smokers only, adenocarcinoma, squamous cell carcinoma, and small cell carcinoma), and ten ovarian cancer outcomes, including serous, mucinous, clear cell, and endometrial subtypes.